I'm expecting that the upcoming trial results will determine the timeline for considering offers - if the PMS outcomes are replicated, then it would indicate with a deal of confidence, that NNZ-2591 would be beneficial for people with other disorders both within and without of the autism spectrum.
The timing of the AGM on 28th May would seem almost perfect - can't wait to attend.
Ann: 2023 Annual Report to shareholders, page-192
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.98 |
Change
0.280(2.20%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $13.02 | $13.06 | $12.89 | $4.380M | 337.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 1725 | $12.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.98 | 1733 | 10 |
View Market Depth
| Last trade - 13.04pm 17/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |